Functional genetic screening and pharmacological approaches demonstrated a strong dependency from EGFR-MEK pathway, which we exploited as a combinatorial treatment (EGFR plus MEK inhibition) on CRC cells and xenopatients. This evidence concerns the gene EGFR and colorectal carcinoma.